Roche and Xenon ink pact on anemia therapies

Roche Holdings has agreed to a deal with Xenon to develop new anemia therapies. Roche will invest $7 million and pay up to $44 million in milestones for the first product. Roche gains an option to commercialize protein therapeutics targeting hemojuvelin as well as a licensing option for small molecule inhibitors of HJV.

- read the AFX report on the deal

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.